Connect with us

Biotech

Besins Healthcare Enters the Spanish Market and Invests 25M in a Plant

Besins Healthcare’s products include natural progesterone for pregnant women, transdermal gel for testosterone deficiency syndrome, and estradiol replacement therapies during menopause. Specifically, at the Muel plant, Besins Manufacturing España will have the capacity to produce drugs in the form of capsules and gels. One of the company’s mainstays is constant research

Published

on

Besins Healthcare enters the market in Spain. The Monaco-based company, which specializes in novel therapies for gynecology, fertility, obstetrics, endocrinology, and andrology, has chosen the town of Muel (Zaragoza) to set up its first factory in Spain, a project that will involve an investment of $26.4 million (€25 million), according to a press release from the Government of Aragon.

The multinational pharmaceutical company has already acquired a 9,800-square-meter warehouse in the El Pitarco industrial estate in the town of Zaragoza to carry out this investment. Thanks to this project, 150 jobs will be created.

The announcement of the acquisition of this site was made this Thursday by Javier Lambán, President of Aragón, after the meeting held with the multinational’s managers, who detailed the details of the project, and the Regional Minister of Economy, Marta Gastón. Work is already underway on the adaptation of the building, and later part of the equipment will be installed so that it can be tested starting this summer.

The plant is expected to start manufacturing in the second half of 2022. For the time being, the investment of $26.4 million (€25 million) includes the acquisition of land, adaptation of the existing plant, and the new facilities. However, according to company sources, there could be additional investments in the future, “given that we are talking about a stable process that will last for decades”, according to the regional executive in the note.

If you want to find more details about Besins Healthcare and to find other business news from the biotech sector and not only, download for free our companion app Born2Invest.

SEE ALSO  Entrepreneurship: the Region Laâyoune-Sakia El Hamra Launches the Program RIYADA

Besins Healthcare will start manufacturing in the new factory in the second half of 2022

Lambán has assured that the Aragonese Government has made all the administrative instruments available for this successful project with the possibility of having greater scope in the future and therefore will also provide support also at the level of vocational training and aid from the Department of Economy inhabited for the promotion of the pharmaceutical sector.

Besins Healthcare is a family company founded by Abel Besins in 1885. Four generations later, his successors continue to lead the group. Today it produces and markets more than thirty different products that are prescribed in one hundred countries around the world.

One of the company’s mainstays is constant research. Thanks to it, it has been possible to discover innovative technologies that have an impact on improving the health of women and men throughout their lives.

Besins Healthcare’s products include natural progesterone for pregnant women, transdermal gel for testosterone deficiency syndrome, and estradiol replacement therapies during menopause. Specifically, at the Muel plant, Besins Manufacturing España will have the capacity to produce drugs in the form of capsules and gels.

__

(Featured image by DarkoStojanovic via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Olivia McCall is passionate about education, women and children’s rights, and the environment. A long-time investor, she covers news about the latest stocks (lately marijuana and tech), IPOs and indices, and is always on the lookout for socially responsible startups. She also writes about the food sector, and has a keen interest on cryptocurrencies.

Continue Reading